AMPK activation by Aldometanib from Bigujing improves metabolic and cognitive dysfunction in aging mice.
- DOI
- 10.1007/s11011-026-01985-8
- Published
- 2026 Sep 12
- Container
- Metabolic brain disease
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s11011-026-01985-8,
title = {AMPK activation by Aldometanib from Bigujing improves metabolic and cognitive dysfunction in aging mice.},
author = {Wang X and Zhang S and Wang Q and Leng J and Zhang M and Wan G and Zhu Y and Huang B and Ran J},
year = {2026},
journal = {Metabolic brain disease},
doi = {10.1007/s11011-026-01985-8},
url = {https://doi.org/10.1007/s11011-026-01985-8}
}RIS
TY - JOUR TI - AMPK activation by Aldometanib from Bigujing improves metabolic and cognitive dysfunction in aging mice. AU - Wang X AU - Zhang S AU - Wang Q AU - Leng J AU - Zhang M AU - Wan G AU - Zhu Y AU - Huang B AU - Ran J PY - 2026 JO - Metabolic brain disease DO - 10.1007/s11011-026-01985-8 UR - https://doi.org/10.1007/s11011-026-01985-8 ER -
APA
X, W., S, Z., Q, W., J, L., M, Z., G, W., Y, Z., B, H., & J, R. (2026). AMPK activation by Aldometanib from Bigujing improves metabolic and cognitive dysfunction in aging mice.. Metabolic brain disease. https://doi.org/10.1007/s11011-026-01985-8
Source records
- pubmed · retrieved 2026-09-26T03:22:20.863Z